A patient is taking levetiracetam (Keppra) to treat seizures. Routine education for levetiracetam includes reminding them:

Levetiracetam (Keppra) is a broad-spectrum anticonvulsant used in the management of partial-onset seizures, myoclonic seizures, and generalized tonic-clonic seizures. It works by modulating neurotransmitter release through binding to synaptic vesicle protein SV2A, helping stabilize neuronal activity. Patient education is essential to ensure adherence and prevent breakthrough seizures. One of the most important safety concerns with anticonvulsants is avoiding sudden discontinuation. Rationale: A. Weight loss is not a characteristic or clinically significant adverse effect that requires routine monitoring in patients taking Levetiracetam (Keppra). In some cases, patients may experience decreased appetite or weight changes, but this is not a primary safety concern. Routine counseling focuses more on neuropsychiatric effects such as irritability, mood changes, or depression rather than weight monitoring. B. Photosensitivity is not a known adverse effect of Levetiracetam (Keppra). Unlike some medications such as tetracyclines or certain diuretics, levetiracetam does not significantly increase sensitivity to sunlight. Therefore, routine sunscreen use is not specifically required as part of standard medication counseling for this drug. C. An annual eye exam is not a standard monitoring requirement for patients on Levetiracetam (Keppra). Some anticonvulsants, like vigabatrin, require ophthalmologic monitoring due to risk of visual field defects, but levetiracetam does not have known ocular toxicity that necessitates routine eye screening. D. Abrupt discontinuation of Levetiracetam (Keppra) can lead to withdrawal seizures or increased seizure frequency due to sudden loss of neuronal stabilization. Patients should be instructed to taper the medication gradually under medical supervision rather than stopping it suddenly. This is a key safety teaching point for all anticonvulsant therapies to prevent rebound seizure activity.